



(51) International Patent Classification:

A61K 31/336 (2006.01) C07D 303/02 (2006.01)
A61K 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/059814

(22) International Filing Date:

10 November 2015 (10.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/077,712 10 November 2014 (10.11.2014) US

(71) Applicant: DEL MAR PHARMACEUTICALS
[CA/CA]; Suite 115--887 Great Northern Way, Vancouver,
British Columbia V5T 4T5 (CA).

(72) Inventors; and

(71) Applicants : BACHA, Jeffrey, A. [CA/CA]; Del Mar
Pharmaceuticals, Suite 115--887 Great Northern Way,
Vancouver, British Columbia V5T 4T5 (CA). BROWN,
Dennis, M. [US/US]; 3475 Edison Way, Suite R, Menlo
Park, CA 94025 (US). STEINØ, Anne [CA/CA]; 2006-
6385 Hawthorn Lane, Vancouver, British Columbia V6T
1Z4 (CA). FOUSE, Shaun [US/US]; University of Cali-

fornia, San Francisco, 530 Parnassus, San Francisco, CA
94313 (US).

(74) Agent: FARBER, Michael, B.; Ditthavong & Steiner,
P.C., 44 Canal Center Plaza, Suite 322, Alexandria, VA
22314 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME




FIG. 1

(57) Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, —
GW, KM, ML, MR, NE, SN, TD, TG).

*before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*